Tribulations of Recent Cardiology Trials, the Audacity of Hope, and HOPE-3

Canadian Journal of Cardiology

Volumn 32, Issue 3, 2016, Pages 275-277

  Waters, David D ^a   Chau, Katherine Hsin Yu ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANACETRAPIB; ATORVASTATIN; CANDESARTAN; DALCETRAPIB; DARAPLADIB; EVACETRAPIB; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCHLOROTHIAZIDE; PHOSPHOLIPASE A2; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TORCETRAPIB; BENZIMIDAZOLE DERIVATIVE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TETRAZOLE DERIVATIVE;

ATHEROSCLEROSIS; CARDIOLOGY; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); DIASTOLIC BLOOD PRESSURE; EDITORIAL; HUMAN; PRIMARY PREVENTION; RISK REDUCTION; SYSTOLIC BLOOD PRESSURE; BLOOD; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; FEMALE; MALE; PHYSIOLOGY; PROCEDURES;

BENZIMIDAZOLES; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; MALE; PRIMARY PREVENTION; ROSUVASTATIN CALCIUM; TETRAZOLES;

EID: 84959568573     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2015.08.020     Document Type: Editorial

References (26)

1. Gordon D.J., Probstfield J.L., Garrison R.J., et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989, 79:8-15.
2. Barter P.J., Caulfield M., Eriksson M., et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007, 357:2109-2122.
3. Schwartz G.G., Olsson A.G., Abt M., et al. Effect of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012, 367:2089-2099.
4. Barter P.J., Rye K.A. Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk. J Lipid Res 2012, 53:1755-1766.
5. Nissen S.E., Tsunoda T., Tuzcu E.M., et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes. JAMA 2003, 290:2292-2300.
6. Tardif J.C., Grégoire J., L'Allier P.L., et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 2007, 297:1675-1682.
7. Waksman R., Torguson R., Kent K.M., et al. A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome. J Am Coll Cardiol 2010, 55:2727-2735.
8. Tardif J.C., Ballantyne C.M., Barter P., et al. Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial. Eur Heart J 2014, 35:3277-3286.
9. Rader D.J., Hovingh G.K. HDL and cardiovascular disease. Lancet 2014, 384:618-625.
10. Kolodgie F.D., Burke A.P., Skorija K.S., et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 2006, 26:2523-2529.
11. Casas J.P., Ninio E., Panayiotou A., et al. PLA2G7 genotype, lipoprotein-associated phospholipase A2 activity, and coronary heart disease risk in 10 494 cases and 15 624 controls of European ancestry. Circulation 2010, 121:2284-2293.
12. Serruys P.W., Garcia-Garcia H.M., Buszman P., et al. Effects of the direct lipoprotein-associated phospholipase A2 inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 2008, 118:1172-1182.
13. White H.D., Held C., et al. Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med 2014, 370:1702-1711. STABILITY Investigators.
14. O'Donoghue M.L., Braunwald E., White H.D., et al. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. JAMA 2014, 312:1006-1015.
15. Nicholls S.J., Kastelein J.J., Schwartz G.G., et al. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial. JAMA 2014, 311:252-262.
16. Fordyce C.B., Roe M.T., Ahmad T., et al. Cardiovascular drug development. Is it dead or just hibernating?. J Am Coll Cardiol 2015, 65:1567-1582.
17. Baigent C., Blackwell L., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010, 376:1760-1781. Cholesterol Treatment Trialists' (CTT) Collaboration.
18. Waters D.D. LDL-cholesterol lowering and renal outcomes. Curr Opin Lipidol 2015, 26:195-199.
19. Preiss D., Campbell R.T., Murray H.M., et al. The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials. Eur Heart J 2015, 36:1536-1546.
20. Lonn E., Bosch J., Pogue J., et al. Novel approaches in primary cardiovascular disease prevention: the HOPE-3 trial rationale, design, and participants' baseline characteristics. Can J Cardiol 2016, 32:311-318.
21. Baigent C., Blackwell L., et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 2015, 385:1397-1405. Cholesterol Treatment Trialists' (CTT) Collaboration.
22. Ridker P.M., Danielson E., Fonseca F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195-2207.
23. Zanchetti A., Thomopoulos C., Parati G. Randomized controlled trials of blood pressure lowering in hypertension: a critical reappraisal. Circ Res 2015, 116:1058-1073.
24. James P.A., Oparil S., Carter B.L., et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth joint national committee (JNC 8). JAMA 2014, 311:507-520.
25. Lewington S., Clarke R., Qizilbash N., Peto R., Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360:1903-1913.
26. Sundström J., Arima H., et al. Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet 2014, 384:591-598. Blood Pressure Lowering Treatment Trialists' Collaboration.